Bioscience Valuation BSV GmbH

BioScience Valuation (BSV) is a consulting company working at the intersection of life sciences and finance. BSV is a trusted partner for Pharma and Biotech companies and their investors, with a 500+ mandates track record of private and public clients in Europe, the US, and worldwide.
Since 2000, the company has been at the forefront of translating scientific innovation into financial value. Our services cover the entire spectrum of commercial, R&D and financial analyses and deliver unparalleled evidence-based assessments. Based on our profound subject expertise and comprehensive database coverage, our appraisals demonstrate the route to value creation from seed stage to IPO and beyond.
Our strategic alliances enable us to reach out into the US and other markets and to communicate client equity stories within the international investor community.



BSV at a glance:

BSV provides a broad range of services tailored to the specific needs of each client:

Pharmaceutical companies
• Implementation of value-driven R&D portfolio management
• Optimization of R&D productivity, resource/capacity planning
• Forecast of a drug´s sales potential, determination of project value and prioritization in the portfolio context
• Competitive intelligence
• Assessment of in-licensing candidates and potential M&A transactions

Biotech/Medtech companies
• Assessment and valuation of technology platforms, developement products, and the company’s growth potential
• Indication scoping (identification and prioritization of therapeutic indications based on the company’s technology)
• Definition of USP and outline of expected value evolution to create unique equity stories                          • Support of business development and fundraising campaigns
• Negotiation of term sheets and agreements to maximize value

• Opportunity scouting, support of internal due diligence
• Assessment of single assets and entire R&D programs
• Optimization of program/portfolio strategy
• Support of relationship building with US investor community

Strategic alliances
• LaVoie Health Science, USA (Boston, New York)
• FCF Fox Corporate Finance GmbH, Germany (Munich)

Date of Incorporation 2000



Joachim M. Greuel, Ph.D., MBA, Managing Director,
Kerstin M. Bode-Greuel, MD, PhD.
Managing Director,
Address Am Zigeunerbergl 3
82491 Grainau
Telephone/Telefax +49 8821 966 979-10 /-29
Email contact@bioscience-valuation.com
Web Address www.bioscience-valuation.com
Social Media LinkedIn


Beiträge von/mit Bioscience Valuation

Strategic collaboration between NLC Health Ventures and BioScience Valuation (BSV)

This news is based on a press release from NLC Health Ventures and BioSicence Valuation (BSV). NLC Health Ventures and BioSicence Valuation (BSV) initiate a...

Rückblick: 25 Jahre Biotech – der Finance Day zum Jubiläum

Mehr teilen, um Innovationen zu fördern, und präzisere Technologien für die klinische Anwendung – so lauteten einige der Erkenntnisse, die beim Finance Day, anlässlich...

The advantage of early-stage biotech investing

The 35% downturn of the NASDAQ Biotechnology Index between September 2021 and June 2022 sparked discussions as to whether there may be biotech investment...

Comparing late-stage vs. early-stage investment strategies

It is generally believed that, as projects advance in discovery research, little value is created because the products are still ­years away from the...

Im Auge des Sturms herrscht gelassene Ruhe

Die „Plattform Life Sciences“ lud am 22. Juni ihre Netzwerkpartner in den Faculty Club G2B (Gateway to Biotech) im Innovations- und Gründerzentrum Biotechnologie (IZB)...